|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-0.46/-0.29
|
企業價值
296.34M
|
資產負債 |
每股賬面淨值
1.47
|
現金流量 |
現金流量率
--
|
損益表 |
收益
37.75M
|
每股收益
0.73
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States. |